secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2026-10-05T20:10:13+00:00
Accession:  0001193125-26-414118
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Korro Bio doses first cohort in Phase 1/2 ANCHOR trial of KRRO-121 for urea cycle disorders
--------------------------------------------------------------------------------

- First cohort of healthy volunteers received a single 2mg/kg dose of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide (REO) targeting hyperammonemia in UCD and hepatic encephalopathy.
- ANCHOR Part 1: placebo-controlled SAD in up to 30 healthy volunteers across up to 5 cohorts, then MAD in up to 20 subjects across 2 cohorts; enrollment is in Australia (NCT07773246).
- ANCHOR Part 2: Phase 2 multiple-dose study in up to 15 UCD patients across all UCD genotypes, subject to regulatory approval.
- Dosing in UCD patients expected to begin in the first half of 2027, with an interim readout expected in the second half of 2027.
- CEO Ram Aiyar said KRRO-121 blunted ammonia excursions in multiple preclinical studies across different mutations; trial first aims to establish safety, then activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526414118/0001193125-26-414118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526414118/krro-20261005.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-414118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer